Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
POLBF
)
0.1180
UNCHANGED
Last Price
Updated: 3:19 PM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about POLBF
< Previous
1
2
3
Next >
Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
July 25, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Change of Registered Address
July 01, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
May 08, 2024
Via
ACCESSWIRE
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
May 08, 2024
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the...
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
April 30, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
April 29, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
April 29, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
April 28, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
March 19, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
February 11, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
April 29, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Director Share Purchase
February 19, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
February 14, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
January 16, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
December 19, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
December 11, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Directorate Change
November 30, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
November 21, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
November 16, 2023
Via
ACCESSWIRE
Former Amryt Pharma Leadership Team join Poolbeg
November 09, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
November 03, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
November 01, 2023
Via
ACCESSWIRE
Poolbeg Pharma unveils new collaboration agreement
October 18, 2023
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company has signed a new collaboration agreement with an...
Via
TheNewswire.com
Poolbeg Partners with a Nasdaq-Listed Biopharma
October 17, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
September 29, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
September 19, 2023
Via
ACCESSWIRE
Poolbeg Pharma "moving forward rapidly" with POLB001
September 13, 2023
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023....
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
September 13, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza Drug Targets
June 29, 2023
Via
ACCESSWIRE
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
June 29, 2023
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant...
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
